American Society of Hematology sent one of their many missives today. Many of
them aren’t really relevant to me, but this one had an interesting article – “Venous
thromboembolism in cancer patients: a population-based cohort study”. You
can read it by
The take home message is that the 12-month cumulative incidence of VTE is currently 3% following cancer diagnosis, which is 9 times higher than in the general population, and that over the past two decades, VTE risk in cancer patients increased 3-fold overall and 6-fold in those using chemotherapy or targeted therapy.
Should the laboratories be offering something in the way of screening in light of this?